MedTrace Logo

Effects of Dapagliflozin and Metformin on Vascular Function in Newly-Diagnosed Treatment-Naive Type 2 Diabetes

NCT05440591 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2022-07-01

No results posted yet for this study

Summary

Trial Design: This is a 12 week randomised controlled open label trial comparing the impact of Dapagliflozin, Metformin and combination therapy on vascular function in newly diagnosed T2DM patients.

Conditions

Interventions

DRUG

Dapagliflozin

Dapagliflozin 10mg tablets

DRUG

MetFORMIN 500 Mg Oral Tablet

Metformin 500 mg tablets twice daily

DRUG

Dapagliflozin / metFORMIN Pill

Combination pill

Sponsors & Collaborators

  • Tan Tock Seng Hospital

    lead OTHER

Principal Investigators

  • Rinkoo Dalan · Tan Tock Seng Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2023-05-10
Completion
2023-05-10

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05440591 on ClinicalTrials.gov